Intraperitoneal delivery of platinum with in-situ crosslinkable hyaluronic acid gel for local therapy of ovarian cancer

Biomaterials

Volumn 37, Issue , 2015, Pages 312-319

  Cho, Eun Jung ^a   Sun, Bo ^a   Doh, Kyung Oh ^a,b   Wilson, Erin M ^a   Torregrosa Allen, Sandra ^c   Elzey, Bennett D ^c,d   Yeo, Yoon ^a,e  

^a PURDUE UNIVERSITY   (United States)

^b Yeungnam University College of Medicine   (South Korea)

^c PURDUE UNIVERSITY   (United States)

^d PURDUE UNIVERSITY   (United States)

^e PURDUE UNIVERSITY   (United States)

Author keywords

Drug delivery; Empty carriers; Hyaluronic acid; Intraperitoneal chemotherapy; Ovarian cancer; Platinum

Indexed keywords

BIOCOMPATIBILITY; BIODEGRADABILITY; CHEMOTHERAPY; CONTROLLED DRUG DELIVERY; DEGRADATION; DISEASES; DRUG DELIVERY; MOLECULAR BIOLOGY; NANOPARTICLES; ORGANIC ACIDS; PLATINUM; TARGETED DRUG DELIVERY; TUMORS;

ANTI-TUMOR EFFICACY; BIOLOGICAL EFFECTS; DEGRADATION PRODUCTS; INTRAPERITONEAL; OVARIAN CANCERS; POTENTIAL BENEFITS; RECEPTOR-MEDIATED ENDOCYTOSIS; SUSTAINED RELEASE;

HYALURONIC ACID;

CISPLATIN; HYALURONIC ACID; PLATINUM NANOPARTICLE; ANTINEOPLASTIC AGENT; CROSS LINKING REAGENT; DRUG CARRIER; FLUORESCENT DYE; GEL; HERMES ANTIGEN; NANOPARTICLE; PLATINUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOCOMPATIBILITY; BIODEGRADABILITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SIZE; CONTROLLED STUDY; CROSS LINKING; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RETENTION; ENDOCYTOSIS; FEMALE; HUMAN; HUMAN CELL; HYDROGEL; LOCAL THERAPY; MOUSE; NANOPHARMACEUTICS; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CANCER; PERITONEAL CAVITY; PRIORITY JOURNAL; SINGLE DRUG DOSE; SKOV3 CELL LINE; SUSTAINED DRUG RELEASE; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG EFFECTS; GEL; INTRAPERITONEAL DRUG ADMINISTRATION; KINETICS; LUMINESCENCE; MAXIMUM TOLERATED DOSE; METABOLISM; OVARIAN NEOPLASMS; PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; CROSS-LINKING REAGENTS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; FEMALE; FLUORESCENT DYES; GELS; HUMANS; HYALURONIC ACID; INJECTIONS, INTRAPERITONEAL; KINETICS; LUMINESCENCE; MAXIMUM TOLERATED DOSE; MICE, INBRED BALB C; NANOPARTICLES; OVARIAN NEOPLASMS; PLATINUM; TUMOR BURDEN;

EID: 84922251589     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.10.039     Document Type: Article

References (58)

1. Chambers S.K., Chow H.-H.S., Janicek M.F., Cragun J.M., Hatch K.D., Cui H., et al. Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer. Clin Cancer Res 2012, 18:2668-2678.
2. Hasovits C., Clarke S. Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics. Clin Pharmacokinet 2012, 51:203-224.
3. Lu Z., Wang J., Wientjes M.G., Au J.L.S. Intraperitoneal therapy for peritoneal cancer. Future Oncol 2010, 6:1625-1641.
4. Dedrick R.L., Myers C.E., Bungay P.M., DeVita V.T. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978, 62:1-11.
5. Markman M. Intraperitoneal drug delivery of antineoplastics. Drugs 2001, 61:1057-1065.
6. Nissan A., Stojadinovic A., Garofalo A., Esquivel J., Piso P. Evidence-based medicine in the treatment of peritoneal carcinomatosis: past, present, and future. JSurg Oncol 2009, 100:335-344.
7. Zahedi P., Stewart J., De Souza R., Piquette-Miller M., Allen C. An injectable depot system for sustained intraperitoneal chemotherapy of ovarian cancer results in favorable drug distribution at the whole body, peritoneal and intratumoral levels. JControl Release 2012, 158:379-385.
8. Markman M. Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol 2003, 4:277-283.
9. Marchettini P., Stuart O.A., Mohamed F., Yoo D., Sugarbaker P.H. Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model. Cancer Chemother Pharmacol 2002, 49:499-503.
10. Nemes K.B., Abermann M., Bojti E., Grezal G., Al-Behaisi S., Klebovich I. Oral, intraperitoneal and intravenous pharmacokinetics of deramciclane and its N-desmethyl metabolite in the rat. JPharm Pharmacol 2000, 52:47-51.
11. Krasner C.N., Roche M., Horowitz N.S., Supko J.G., Lee S.I., Oliva E. Case records of the Massachusetts general hospital. Case 11-2006. A 54-year-old woman with a mass in the pelvis. NEngl J Med 2006, 354:1615-1625.
12. Hirano K., Hunt C.A. Lymphatic transport of liposome-encapsulated agents: effects of liposome size following intraperitoneal administration. JPharm Sci 1985, 74:915-921.
13. Lu H., Li B., Kang Y., Jiang W., Huang Q., Chen Q., et al. Paclitaxel nanoparticle inhibits growth of ovarian cancer xenografts and enhances lymphatic targeting. Cancer Chemother Pharmacol 2007, 59:175-181.
14. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. NEngl J Med 2006, 354:34-43.
15. Francis P., Rowinsky E., Schneider J., Hakes T., Hoskins W., Markman M. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study. JClin Oncol 1995, 13:2961-2967.
16. Tsubamoto H., Takeuchi S., Ito K., Miyagi Y., Toyoda S., Inoue K., et al. Feasibility and efficacy of intraperitoneal docetaxel administration as salvage chemotherapy for malignant gynaecological ascites. JObstet Gynaecol 2014, 1-5.
17. Hall J.C., Heel K.A., Papadimitriou J.M., Platell C. The pathobiology of peritonitis. Gastroenterology 1998, 114:185-196.
18. Yeo Y., Adil M., Bellas E., Astashkina A., Chaudhary N., Kohane D.S. Prevention of peritoneal adhesions with an in situ cross-linkable hyaluronan hydrogel delivering budesonide. JControl Release 2007, 120:178-185.
19. Yeo Y., Bellas E., Highley C.B., Langer R., Kohane D.S. Peritoneal adhesion prevention with an in situ cross-linkable hyaluronan gel containing tissue-type plasminogen activator in a rabbit repeated injury model. Biomaterials 2007, 28:3704-3713.
20. Yeo Y., Ito T., Bellas E., Highley C.B., Marini R., Kohane D.S. In situ cross-linkable hyaluronan hydrogels containing polymeric nanoparticles for preventing postsurgical adhesions. Ann Surg 2007, 245:819-824.
21. Bajaj G., Kim M.R., Mohammed S.I., Yeo Y. Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors. JControl Release 2012, 158:386-392.
22. Yeo Y., Highley C.B., Bellas E., Ito T., Marini R., Langer R., et al. In situ cross-linkable hyaluronic acid hydrogels prevent post-operative abdominal adhesions in a rabbit model. Biomaterials 2006, 27:4698-4705.
23. Kohane D.S., Tse J.Y., Yeo Y., Padera R., Shubina M., Langer R. Biodegradable polymeric microspheres and nanospheres for drug delivery in the peritoneum. JBiomed Mater Res 2006, 77A:351-361.
24. Dobson A., Robinson S.D. Carboxylato complexes of the platinum group metals. Platin Met Rev 1976, 20:56-63.
25. Jeong Y.-I., Kim S.-T., Jin S.-G., Ryu H.-H., Jin Y.-H., Jung T.-Y., et al. Cisplatin-incorporated hyaluronic acid nanoparticles based on ion-complex formation. JPharm Sci 2008, 97:1268-1276.
26. Cai S., Xie Y., Davies N.M., Cohen M.S., Forrest M.L. Pharmacokinetics and disposition of a localized lymphatic polymeric hyaluronan conjugate of cisplatin in rodents. JPharm Sci 2010, 99:2664-2671.
27. Cai S., Xie Y., Bagby T.R., Cohen M.S., Forrest M.L. Intralymphatic chemotherapy using a hyaluronan-cisplatin conjugate. JSurg Res 2008, 147:247-252.
28. Cannistra S.A. Cancer of the ovary. NEngl J Med 2004, 351:2519-2529.
29. Jelovac D., Armstrong D.K. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin 2011, 61:183-203.
30. Nishiyama N., Kataoka K. Preparation and characterization of size-controlled polymeric micelle containing cis-dichlorodiammineplatinum(II) in the core. JControl Release 2001, 74:83-94.
31. Acute Toxicity Determination. http://dtp.nci.nih.gov/branches/btb/acute_tox.html.
32. Cho H., Lai T.C., Kwon G.S. Poly(ethylene glycol)-block-poly(ε-caprolactone) micelles for combination drug delivery: evaluation of paclitaxel, cyclopamine and gossypol in intraperitoneal xenograft models of ovarian cancer. JControl Release 2013, 166:1-9.
33. Ohya Y., Masunaga T., Ouchi T., Ichinose K., Nakashima M., Ichikawa M., et al. Antitumor drug delivery by dextran derivatives immobilizing platinum complex (II) through coordination bond. ACS Symp Ser 1998, 709:266-278.
34. Dynamic light scattering- common terms defined. http://www.malvern.com/en/pdf/secure/WP111214DLSTermsDefined.pdf.
35. Auzenne E., Ghosh S.C., Khodadadian M., Rivera B., Farquhar D., Price R.E., et al. Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts. Neoplasia 2007, 9:479-486.
36. Choi K.Y., Chung H., Min K.H., Yoon H.Y., Kim K., Park J.H., et al. Self-assembled hyaluronic acid nanoparticles for active tumor targeting. Biomaterials 2010, 31:106-114.
37. Lesley J., Hascall V.C., Tammi M., Hyman R. Hyaluronan binding by cell surface CD44. JBiol Chem 2000, 275:26967-26975.
38. Ween M.P., Oehler M.K., Ricciardelli C. Role of versican, hyaluronan and CD44 in ovarian cancer metastasis. Int J Mol Sci 2011, 12:1009-1029.
39. Zagorianakou N., Stefanou D., Makrydimas G., Zagorianakou P., Briasoulis E., Karavasilis B., et al. CD44s expression, in benign, borderline and malignant tumors of ovarian surface epithelium. Correlation with p53, steroid receptor status, proliferative indices (PCNA, MIB1) and survival. Anticancer Res 2004, 24:1665-1670.
40. Kayastha S., Freedman A.N., Piver M.S., Mukkamalla J., Romero-Guittierez M., Werness B.A. Expression of the hyaluronan receptor, CD44S, in epithelial ovarian cancer is an independent predictor of survival. Clin Cancer Res 1999, 5:1073-1076.
41. Afify A.M., Ferguson A.W., Davila R.M., Werness B.A. Expression of CD44S and CD44v5 is more common in stage III than in stage I serous ovarian carcinomas. Appl Immunohistochem Mol Morphol 2001, 9:309-314.
42. Cannistra S.A., Abu-Jawdeh G., Niloff J., Strobel T., Swanson L., Andersen J., et al. CD44 variant expression is a common feature of epithelial ovarian cancer: lack of association with standard prognostic factors. JClin Oncol 1995, 13:1912-1921.
43. De Stefano I., Battaglia A., Zannoni G., Prisco M., Fattorossi A., Travaglia D., et al. Hyaluronic acid-paclitaxel: effects of intraperitoneal administration against CD44(+) human ovarian cancer xenografts. Cancer Chemother Pharmacol 2011, 68:107-116.
44. Picaud L., Thibault B., Mery E., Ouali M., Martinez A., Delord J.P., et al. Evaluation of the effects of hyaluronic acid-carboxymethyl cellulose barrier on ovarian tumor progression. JOvarian Res 2014, 7:40.
45. Jackson D.G. Biology of the lymphatic marker LYVE-1 and applications in research into lymphatic trafficking and lymphangiogenesis. APMIS 2004, 112:526-538.
46. Li S.-D., Howell S.B. CD44-targeted microparticles for delivery of cisplatin to peritoneal metastases. Mol Pharm 2009, 7:280-290.
47. Laurent T.C., Laurent U.B.G., Fraser J.R.E. The structure and function of hyaluronan: an overview. Immunol Cell Biol 1996, 74:A1-A7.
48. Fakhari A., Berkland C. Applications and emerging trends of hyaluronic acid in tissue engineering, as a dermal filler and in osteoarthritis treatment. Acta Biomater 2013, 9:7081-7092.
49. Kosaki R., Watanabe K., Yamaguchi Y. Overproduction of hyaluronan by expression of the hyaluronan synthase Has2 enhances anchorage-independent growth and tumorigenicity. Cancer Res 1999, 59:1141-1145.
50. Liu N., Gao F., Han Z., Xu X., Underhill C.B., Zhang L. Hyaluronan synthase 3 overexpression promotes the growth of TSU prostate cancer cells. Cancer Res 2001, 61:5207-5214.
51. Tan B., Wang J.H., Wu Q.D., Kirwan W.O., Redmond H.P. Sodium hyaluronate enhances colorectal tumour cell metastatic potential invitro and invivo. Br J Surg 2001, 88:246-250.
52. Mytar B., Woloszyn M., Szatanek R., Baj-Krzyworzeka M., Siedlar M., Ruggiero I., et al. Tumor cell-induced deactivation of human monocytes. JLeukoc Biol 2003, 74:1094-1101.
53. Mytar B., Siedlar M., Woloszyn M., Colizzi V., Zembala M. Cross-talk between human monocytes and cancer cells during reactive oxygen intermediates generation: the essential role of hyaluronan. Int J Cancer 2001, 94:727-732.
54. Sironen R.K., Tammi M., Tammi R., Auvinen P.K., Anttila M., Kosma V.M. Hyaluronan in human malignancies. Exp Cell Res 2011, 317:383-391.
55. Koyama H., Hibi T., Isogai Z., Yoneda M., Fujimori M., Amano J., et al. Hyperproduction of hyaluronan in neu-induced mammary tumor accelerates angiogenesis through stromal cell recruitment. Am J Pathol 2007, 170:1086-1099.
56. Zoltan-Jones A., Huang L., Ghatak S., Toole B.P. Elevated hyaluronan production induces mesenchymal and transformed properties in epithelial cells. JBiol Chem 2003, 278:45801-45810.
57. Emoto S., Yamaguchi H., Kamei T., Ishigami H., Suhara T., Suzuki Y., et al. Intraperitoneal administration of cisplatin via an in situ cross-linkable hyaluronic acid-based hydrogel for peritoneal dissemination of gastric cancer. Surg Today 2014, 44:919-926.
58. Zeng C., Toole B.P., Kinney S.D., Kuo J.W., Stamenkovic I. Inhibition of tumor growth invivo by hyaluronan oligomers. Int J Cancer 1998, 77:396-401.